-
2
-
-
84973351677
-
Primary Malignant Melanoma of Pleura: A Case Report and Literature Review
-
Agarwal P, Nambiyar K, Manju K, Bhardwaj M. Primary Malignant Melanoma of Pleura: A Case Report and Literature Review. Diagn Cytopathol. 2016; 44:648-652.
-
(2016)
Diagn Cytopathol
, vol.44
, pp. 648-652
-
-
Agarwal, P.1
Nambiyar, K.2
Manju, K.3
Bhardwaj, M.4
-
3
-
-
84965150068
-
Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000
-
Bleyer A, O'Leary M, Barr R, Ries LAG. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000. 2006.
-
(2006)
Cancer epidemiology in older adolescents and young adults 15 to 29 years of age, including SEER incidence and survival: 1975-2000
-
-
Bleyer, A.1
O'Leary, M.2
Barr, R.3
Ries, L.A.G.4
-
4
-
-
84924271853
-
Global cancer statistics, 2012
-
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. Cancer J Clin. 2015; 65:87-108.
-
(2015)
Cancer J Clin
, vol.65
, pp. 87-108
-
-
Torre, L.A.1
Bray, F.2
Siegel, R.L.3
Ferlay, J.4
Lortet-Tieulent, J.5
Jemal, A.6
-
6
-
-
25144506469
-
Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors
-
Gandini S, Sera F, Cattaruzza MS, Pasquini P, Zanetti R, Masini C, Boyle P, Melchi CF. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. European Journal of Cancer. 2005; 41:2040-2059.
-
(2005)
European Journal of Cancer
, vol.41
, pp. 2040-2059
-
-
Gandini, S.1
Sera, F.2
Cattaruzza, M.S.3
Pasquini, P.4
Zanetti, R.5
Masini, C.6
Boyle, P.7
Melchi, C.F.8
-
7
-
-
70349575099
-
Surgery and radiotherapy in the treatment of cutaneous melanoma
-
Testori A, Rutkowski P, Marsden J, Bastholt L, Chiarion-Sileni V, Hauschild A, Eggermont AMM. Surgery and radiotherapy in the treatment of cutaneous melanoma. Annals of Oncology. 2009; 20(suppl 6):vi22-vi29.
-
(2009)
Annals of Oncology
, vol.20
, pp. vi22-vi29
-
-
Testori, A.1
Rutkowski, P.2
Marsden, J.3
Bastholt, L.4
Chiarion-Sileni, V.5
Hauschild, A.6
Eggermont, A.M.M.7
-
8
-
-
77954801079
-
Improved survival with ipilimumab in patients with metastatic melanoma
-
Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC. Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine. 2010; 363:711-723.
-
(2010)
New England Journal of Medicine
, vol.363
, pp. 711-723
-
-
Hodi, F.S.1
O'Day, S.J.2
McDermott, D.F.3
Weber, R.W.4
Sosman, J.A.5
Haanen, J.B.6
Gonzalez, R.7
Robert, C.8
Schadendorf, D.9
Hassel, J.C.10
-
9
-
-
74949143594
-
Final version of 2009 AJCC melanoma staging and classification
-
Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S. Final version of 2009 AJCC melanoma staging and classification. Journal of clinical oncology. 2009; 27:6199-6206.
-
(2009)
Journal of clinical oncology
, vol.27
, pp. 6199-6206
-
-
Balch, C.M.1
Gershenwald, J.E.2
Soong, S.-J.3
Thompson, J.F.4
Atkins, M.B.5
Byrd, D.R.6
Buzaid, A.C.7
Cochran, A.J.8
Coit, D.G.9
Ding, S.10
-
10
-
-
33749053823
-
Sentinel-node biopsy or nodal observation in melanoma
-
Morton DL, Thompson JF, Cochran AJ, Mozzillo N, Elashoff R, Essner R, Nieweg OE, Roses DF, Hoekstra HJ, Karakousis CP. Sentinel-node biopsy or nodal observation in melanoma. New England Journal of Medicine. 2006; 355:1307-1317.
-
(2006)
New England Journal of Medicine
, vol.355
, pp. 1307-1317
-
-
Morton, D.L.1
Thompson, J.F.2
Cochran, A.J.3
Mozzillo, N.4
Elashoff, R.5
Essner, R.6
Nieweg, O.E.7
Roses, D.F.8
Hoekstra, H.J.9
Karakousis, C.P.10
-
11
-
-
84859393995
-
CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma
-
Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clinical Cancer Research. 2012; 18:2039-2047.
-
(2012)
Clinical Cancer Research
, vol.18
, pp. 2039-2047
-
-
Prieto, P.A.1
Yang, J.C.2
Sherry, R.M.3
Hughes, M.S.4
Kammula, U.S.5
White, D.E.6
Levy, C.L.7
Rosenberg, S.A.8
Phan, G.Q.9
-
12
-
-
0033989205
-
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
-
Middleton MR, Grob JJ, Aaronson N, Fierlbeck G, Tilgen W, Seiter S, Gore M, Aamdal S, Cebon J, Coates A. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. Journal of Clinical Oncology. 2000; 18:158-158.
-
(2000)
Journal of Clinical Oncology
, vol.18
, pp. 158-158
-
-
Middleton, M.R.1
Grob, J.J.2
Aaronson, N.3
Fierlbeck, G.4
Tilgen, W.5
Seiter, S.6
Gore, M.7
Aamdal, S.8
Cebon, J.9
Coates, A.10
-
13
-
-
32644467549
-
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206
-
Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675, 206. J Clin Oncol. 2005; 23:8968-8977.
-
(2005)
J Clin Oncol
, vol.23
, pp. 8968-8977
-
-
Ribas, A.1
Camacho, L.H.2
Lopez-Berestein, G.3
Pavlov, D.4
Bulanhagui, C.A.5
Millham, R.6
Comin-Anduix, B.7
Reuben, J.M.8
Seja, E.9
Parker, C.A.10
Sharma, A.11
Glaspy, J.A.12
Gomez-Navarro, J.13
-
14
-
-
61449090474
-
Phase I/II trial of tremelimumab in patients with metastatic melanoma
-
Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J Clin Oncol. 2009; 27:1075-1081.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1075-1081
-
-
Camacho, L.H.1
Antonia, S.2
Sosman, J.3
Kirkwood, J.M.4
Gajewski, T.F.5
Redman, B.6
Pavlov, D.7
Bulanhagui, C.8
Bozon, V.A.9
Gomez-Navarro, J.10
Ribas, A.11
-
15
-
-
69949095926
-
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma
-
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res. 2009; 15:5591-5598.
-
(2009)
Clin Cancer Res
, vol.15
, pp. 5591-5598
-
-
Weber, J.1
Thompson, J.A.2
Hamid, O.3
Minor, D.4
Amin, A.5
Ron, I.6
Ridolfi, R.7
Assi, H.8
Maraveyas, A.9
Berman, D.10
Siegel, J.11
O'Day, S.J.12
-
16
-
-
75249100054
-
Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study
-
Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T Jr., Grob JJ, Chesney J, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, doseranging study. Lancet Oncol. 2010; 11:155-164.
-
(2010)
Lancet Oncol
, vol.11
, pp. 155-164
-
-
Wolchok, J.D.1
Neyns, B.2
Linette, G.3
Negrier, S.4
Lutzky, J.5
Thomas, L.6
Waterfield, W.7
Schadendorf, D.8
Smylie, M.9
Guthrie, T.10
Grob, J.J.11
Chesney, J.12
-
17
-
-
82155168544
-
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
-
Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gomez H, Bastholt L, Chasalow SD, Berman D. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med. 2011; 9:204.
-
(2011)
J Transl Med
, vol.9
, pp. 204
-
-
Hamid, O.1
Schmidt, H.2
Nissan, A.3
Ridolfi, L.4
Aamdal, S.5
Hansson, J.6
Guida, M.7
Hyams, D.M.8
Gomez, H.9
Bastholt, L.10
Chasalow, S.D.11
Berman, D.12
-
18
-
-
79955581263
-
A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
-
Hersh EM, O'Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ, Weber JS. A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma. Investigational New Drugs. 2011; 29:489-498.
-
(2011)
Investigational New Drugs
, vol.29
, pp. 489-498
-
-
Hersh, E.M.1
O'Day, S.J.2
Powderly, J.3
Khan, K.D.4
Pavlick, A.C.5
Cranmer, L.D.6
Samlowski, W.E.7
Nichol, G.M.8
Yellin, M.J.9
Weber, J.S.10
-
19
-
-
79959772576
-
Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
-
Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364:2517-2526.
-
(2011)
N Engl J Med
, vol.364
, pp. 2517-2526
-
-
Robert, C.1
Thomas, L.2
Bondarenko, I.3
O'Day, S.4
Weber, J.5
Garbe, C.6
Lebbe, C.7
Baurain, J.F.8
Testori, A.9
Grob, J.J.10
Davidson, N.11
Richards, J.12
Maio, M.13
-
20
-
-
84878570297
-
Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours
-
Millward M, Underhill C, Lobb S, McBurnie J, Meech SJ, Gomez-Navarro J, Marshall MA, Huang B, Mather CB. Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours. Br J Cancer. 2013; 108:1998-2004.
-
(2013)
Br J Cancer
, vol.108
, pp. 1998-2004
-
-
Millward, M.1
Underhill, C.2
Lobb, S.3
McBurnie, J.4
Meech, S.J.5
Gomez-Navarro, J.6
Marshall, M.A.7
Huang, B.8
Mather, C.B.9
-
21
-
-
84874605864
-
Phase III randomized clinical trial comparing tremelimumab with standard-ofcare chemotherapy in patients with advanced melanoma
-
Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, Lorigan P, Kendra KL, Maio M, et al. Phase III randomized clinical trial comparing tremelimumab with standard-ofcare chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31:616-622.
-
(2013)
J Clin Oncol
, vol.31
, pp. 616-622
-
-
Ribas, A.1
Kefford, R.2
Marshall, M.A.3
Punt, C.J.4
Haanen, J.B.5
Marmol, M.6
Garbe, C.7
Gogas, H.8
Schachter, J.9
Linette, G.10
Lorigan, P.11
Kendra, K.L.12
Maio, M.13
-
22
-
-
84908664534
-
Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial
-
Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D, Kirkwood JM. Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA. 2014; 312:1744-1753.
-
(2014)
JAMA
, vol.312
, pp. 1744-1753
-
-
Hodi, F.S.1
Lee, S.2
McDermott, D.F.3
Rao, U.N.4
Butterfield, L.H.5
Tarhini, A.A.6
Leming, P.7
Puzanov, I.8
Shin, D.9
Kirkwood, J.M.10
-
23
-
-
84908354848
-
Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
-
Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, Patnaik A, Dronca R, Zarour H, et al. Anti-programmeddeath-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014; 384:1109-1117.
-
(2014)
Lancet
, vol.384
, pp. 1109-1117
-
-
Robert, C.1
Ribas, A.2
Wolchok, J.D.3
Hodi, F.S.4
Hamid, O.5
Kefford, R.6
Weber, J.S.7
Joshua, A.M.8
Hwu, W.J.9
Gangadhar, T.C.10
Patnaik, A.11
Dronca, R.12
Zarour, H.13
-
24
-
-
84898973055
-
Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab
-
Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov I, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014; 32:1020-1030.
-
(2014)
J Clin Oncol
, vol.32
, pp. 1020-1030
-
-
Topalian, S.L.1
Sznol, M.2
McDermott, D.F.3
Kluger, H.M.4
Carvajal, R.D.5
Sharfman, W.H.6
Brahmer, J.R.7
Lawrence, D.P.8
Atkins, M.B.9
Powderly, J.D.10
Leming, P.D.11
Lipson, E.J.12
Puzanov, I.13
-
25
-
-
84933678156
-
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
-
Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, Lebbe C, Ferraresi V, Smylie M, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015; 16:522-530.
-
(2015)
Lancet Oncol
, vol.16
, pp. 522-530
-
-
Eggermont, A.M.1
Chiarion-Sileni, V.2
Grob, J.J.3
Dummer, R.4
Wolchok, J.D.5
Schmidt, H.6
Hamid, O.7
Robert, C.8
Ascierto, P.A.9
Richards, J.M.10
Lebbe, C.11
Ferraresi, V.12
Smylie, M.13
-
26
-
-
84936147067
-
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
-
Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015; 373:23-34.
-
(2015)
N Engl J Med
, vol.373
, pp. 23-34
-
-
Larkin, J.1
Chiarion-Sileni, V.2
Gonzalez, R.3
Grob, J.J.4
Cowey, C.L.5
Lao, C.D.6
Schadendorf, D.7
Dummer, R.8
Smylie, M.9
Rutkowski, P.10
Ferrucci, P.F.11
Hill, A.12
Wagstaff, J.13
-
27
-
-
84927651609
-
Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
-
Maio M, Grob JJ, Aamdal S, Bondarenko I, Robert C, Thomas L, Garbe C, Chiarion-Sileni V, Testori A, Chen TT, Tschaika M, Wolchok JD. Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. J Clin Oncol. 2015; 33:1191-1196.
-
(2015)
J Clin Oncol
, vol.33
, pp. 1191-1196
-
-
Maio, M.1
Grob, J.J.2
Aamdal, S.3
Bondarenko, I.4
Robert, C.5
Thomas, L.6
Garbe, C.7
Chiarion-Sileni, V.8
Testori, A.9
Chen, T.T.10
Tschaika, M.11
Wolchok, J.D.12
-
28
-
-
84929481482
-
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
-
Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, Shaheen M, Ernstoff MS, Minor D, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015; 372:2006-2017.
-
(2015)
N Engl J Med
, vol.372
, pp. 2006-2017
-
-
Postow, M.A.1
Chesney, J.2
Pavlick, A.C.3
Robert, C.4
Grossmann, K.5
McDermott, D.6
Linette, G.P.7
Meyer, N.8
Giguere, J.K.9
Agarwala, S.S.10
Shaheen, M.11
Ernstoff, M.S.12
Minor, D.13
-
29
-
-
84938205998
-
Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
-
Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, Cranmer LD, Blank CU, O'Day SJ, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumabrefractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16:908-918.
-
(2015)
Lancet Oncol
, vol.16
, pp. 908-918
-
-
Ribas, A.1
Puzanov, I.2
Dummer, R.3
Schadendorf, D.4
Hamid, O.5
Robert, C.6
Hodi, F.S.7
Schachter, J.8
Pavlick, A.C.9
Lewis, K.D.10
Cranmer, L.D.11
Blank, C.U.12
O'Day, S.J.13
-
30
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, Savage KJ, Hernberg MM, Lebbe C, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015; 372:320-330.
-
(2015)
N Engl J Med
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
Hassel, J.C.7
Rutkowski, P.8
McNeil, C.9
Kalinka-Warzocha, E.10
Savage, K.J.11
Hernberg, M.M.12
Lebbe, C.13
-
31
-
-
84929481481
-
Pembrolizumab versus Ipilimumab in Advanced Melanoma
-
Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, Larkin J, Lorigan P, Neyns B, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med. 2015; 372:2521-2532.
-
(2015)
N Engl J Med
, vol.372
, pp. 2521-2532
-
-
Robert, C.1
Schachter, J.2
Long, G.V.3
Arance, A.4
Grob, J.J.5
Mortier, L.6
Daud, A.7
Carlino, M.S.8
McNeil, C.9
Lotem, M.10
Larkin, J.11
Lorigan, P.12
Neyns, B.13
-
32
-
-
84931083080
-
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
-
Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr., Lao CD, Linette GP, Thomas L, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015; 16:375-384.
-
(2015)
Lancet Oncol
, vol.16
, pp. 375-384
-
-
Weber, J.S.1
D'Angelo, S.P.2
Minor, D.3
Hodi, F.S.4
Gutzmer, R.5
Neyns, B.6
Hoeller, C.7
Khushalani, N.I.8
Miller, W.H.9
Lao, C.D.10
Linette, G.P.11
Thomas, L.12
-
33
-
-
84941615057
-
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
-
Buchbinder E, Hodi FS. Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest. 2015; 125:3377-3383.
-
(2015)
J Clin Invest
, vol.125
, pp. 3377-3383
-
-
Buchbinder, E.1
Hodi, F.S.2
-
35
-
-
58049202334
-
Phase I/II study of ipilimumab for patients with metastatic melanoma
-
Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J, Hersh E. Phase I/II study of ipilimumab for patients with metastatic melanoma. Journal of Clinical Oncology. 2008; 26:5950-5956.
-
(2008)
Journal of Clinical Oncology
, vol.26
, pp. 5950-5956
-
-
Weber, J.S.1
O'Day, S.2
Urba, W.3
Powderly, J.4
Nichol, G.5
Yellin, M.6
Snively, J.7
Hersh, E.8
-
36
-
-
84857405450
-
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?
-
Pierard GE, Aubin F, Humbert P. Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma? Dermatol Res Pract. 2012; 2012:182157.
-
(2012)
Dermatol Res Pract
, vol.2012
-
-
Pierard, G.E.1
Aubin, F.2
Humbert, P.3
-
37
-
-
84887862839
-
A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
-
Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol. 2013; 14:1212-1218.
-
(2013)
Nat Immunol
, vol.14
, pp. 1212-1218
-
-
Okazaki, T.1
Chikuma, S.2
Iwai, Y.3
Fagarasan, S.4
Honjo, T.5
-
38
-
-
84879759020
-
Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma
-
Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine. 2013; 369:134-144.
-
(2013)
New England Journal of Medicine
, vol.369
, pp. 134-144
-
-
Hamid, O.1
Robert, C.2
Daud, A.3
Hodi, F.S.4
Hwu, W.-J.5
Kefford, R.6
Wolchok, J.D.7
Hersey, P.8
Joseph, R.W.9
Weber, J.S.10
-
39
-
-
84925222119
-
Nivolumab in previously untreated melanoma without BRAF mutation
-
Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E. Nivolumab in previously untreated melanoma without BRAF mutation. New England journal of medicine. 2015; 372:320-330.
-
(2015)
New England journal of medicine
, vol.372
, pp. 320-330
-
-
Robert, C.1
Long, G.V.2
Brady, B.3
Dutriaux, C.4
Maio, M.5
Mortier, L.6
Hassel, J.C.7
Rutkowski, P.8
McNeil, C.9
Kalinka-Warzocha, E.10
-
40
-
-
84879777241
-
Nivolumab plus ipilimumab in advanced melanoma
-
Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369:122-133.
-
(2013)
N Engl J Med
, vol.369
, pp. 122-133
-
-
Wolchok, J.D.1
Kluger, H.2
Callahan, M.K.3
Postow, M.A.4
Rizvi, N.A.5
Lesokhin, A.M.6
Segal, N.H.7
Ariyan, C.E.8
Gordon, R.A.9
Reed, K.10
Burke, M.M.11
Caldwell, A.12
Kronenberg, S.A.13
-
42
-
-
78650509651
-
Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial
-
Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multipletreatment meta-analysis: an overview and tutorial. J Clin Epidemiol. 2011; 64:163-171.
-
(2011)
J Clin Epidemiol
, vol.64
, pp. 163-171
-
-
Salanti, G.1
Ades, A.E.2
Ioannidis, J.P.3
|